Aditxt Enters Revenue-Sharing Agreement with Cellvera in Connection with Proposed Acquisition of Cellvera

Aditxt Signs Asset Purchase Agreement for 50% Ownership of Global Response Aid (Avigan) with Cellvera and Agility

April 20, 2023

Pharmaceuticals

Aditxt, Inc. signed an asset purchase agreement to acquire 50% ownership of Global Response Aid FZE (GRA), with the other 50% owned by Agility, Inc. The transaction includes $24.5 million consideration (including forgiveness of a $14.5 million loan and $10 million cash) plus future royalties for seven years, granting Aditxt rights to manufacture and market the broad-spectrum antiviral Avigan 200mg worldwide excluding Japan, China, and Russia.

Aditxt Signs Share Exchange Agreement to Acquire AiPharma Global Holdings

December 28, 2021

Healthcare Services

Aditxt (Nasdaq: ADTX) signed a share exchange agreement to acquire AiPharma Global Holdings LLC (AiPharma Global) in a two-step transaction involving an initial closing and a secondary closing, subject to conditions including regulatory, board, shareholder, and Nasdaq approvals. The deal would give Aditxt 9.5% of AiPharma at the initial closing and the remaining 90.5% at the secondary closing, with cash payments and Aditxt share issuance at each step.

Aditxt Acquires Appili Therapeutics

October 10, 2024

Healthcare Services

Aditxt, Inc. announced that Appili Therapeutics shareholders will vote on a proposed acquisition of all issued and outstanding shares of Appili through a plan of arrangement. Appili’s board recommended shareholders vote in favor, and Aditxt intends to use Appili’s infectious disease pipeline (including the FDA-approved LIKMEZ) to expand its reach in combating life-threatening infections and biodefense threats.

Eli Lilly Acquires Adverum Biotechnologies

December 9, 2025

Biotechnology

Eli Lilly and Company agreed to acquire Adverum Biotechnologies in a cash-and-contingent-value-rights tender offer for all outstanding shares. The total consideration is $3.56 per share in cash at closing plus a CVR that could pay up to $8.91 per share upon achievement of specified milestones, with the transaction expected to close in the fourth quarter of 2025.

Genstar Capital Acquires Advarra from Linden Capital Partners

June 6, 2019

Healthcare Services

Genstar Capital has signed and completed a definitive agreement to acquire Advarra, a leading provider of IRB, IBC and research compliance services, from Linden Capital Partners; Linden intends to reinvest as a minority investor upon closing. Advarra, headquartered in Columbia, Maryland, serves pharma, biotech, medical device companies, CROs and academic medical centers (relationships with over 3,200 institutional sites); Genstar plans to expand Advarra’s capabilities and pursue organic growth and strategic acquisitions.

Aditxt, Inc. (via Adifem, Inc.) to Merge with Evofem Biosciences, Inc.

November 6, 2024

Healthcare Services

Evofem Biosciences announced it has secured voting agreements from certain Series E-1 stockholders and convertible noteholders to approve its proposed merger with Aditxt’s subsidiary, Adifem, Inc., under an amended and restated merger agreement. The deal would result in Evofem merging into and becoming a wholly owned subsidiary of Aditxt (with the surviving entity described as Evofem). Closing is subject to conditions including stockholder approval and Aditxt raising sufficient capital for approximately $17 million in cash payments (including funding a senior secured noteholder).